1Blickle JF.Thiazolidinediones:clinical data and perspectives.Diabetes Metab 2001 Apr:27(2 Pt 2):279-85.
2Shltiel AR.Olefsky JM.Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes.Diabetes 1996.45-52.
3Cheng-Lai A.Levine A.Rosiglitazone:an agent from the thiazolidinedione class for the treatment of type 2 diabetes Heart Dis 2000, Jul-Aug,2(4):326-333.
4Werner AL.Travaglini MT.A review of rosiglitazone in type 2 diabetes mellitus.Pharmacotherapy 2001 Sep,21(9):1082-99.
7I wumoto Y,Kosaka K,kuzuya T,et al.Effects of trogliazone.Diabetes Care[J],1996,19(2):151.
8Saftiel AR,Oefsky JM.Thiaxolidinediones in the treatment of insulin resistance and type Ⅱ diabedes[J].Diabetes,1996,45(12):1661.
9Wilson TM,Cobb JE,Cowan DJ,et al.The structure activity relationship between peroxisome proliferator-activited receptor agonist and the antihyerglycemic activity of thiazolidine-diones[J].J Med Chem,1996,39(3):665.
